NLTX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NLTX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Neoleukin Therapeutics's shares outstanding for the quarter that ended in Sep. 2023 was 2.20 Mil.
Neoleukin Therapeutics's quarterly shares outstanding increased from Jun. 2023 (2.20 Mil) to Sep. 2023 (2.20 Mil). It means Neoleukin Therapeutics issued new shares from Jun. 2023 to Sep. 2023 .
Neoleukin Therapeutics's annual shares outstanding increased from Dec. 2021 (2.12 Mil) to Dec. 2022 (2.13 Mil). It means Neoleukin Therapeutics issued new shares from Dec. 2021 to Dec. 2022 .
The historical data trend for Neoleukin Therapeutics's Shares Outstanding (EOP) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Neoleukin Therapeutics Annual Data | |||||||||||||||||||||
Trend | Dec13 | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | |||||||||||
Shares Outstanding (EOP) | Get a 7-Day Free Trial | 1.18 | 1.90 | 2.11 | 2.12 | 2.13 |
Neoleukin Therapeutics Quarterly Data | ||||||||||||||||||||
Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | |
Shares Outstanding (EOP) | Get a 7-Day Free Trial | 2.13 | 2.13 | 2.14 | 2.20 | 2.20 |
For the Biotechnology subindustry, Neoleukin Therapeutics's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Neoleukin Therapeutics's Shares Outstanding (EOP) distribution charts can be found below:
* The bar in red indicates where Neoleukin Therapeutics's Shares Outstanding (EOP) falls into.
Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.
Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.
Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.
Neoleukin Therapeutics (NAS:NLTX) Shares Outstanding (EOP) Explanation
A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.
Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.
Be Aware
Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.
Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.
If net earnings is less than 10%, likely to be in a highly competitive business.
Thank you for viewing the detailed overview of Neoleukin Therapeutics's Shares Outstanding (EOP) provided by GuruFocus.com. Please click on the following links to see related term pages.
Baker Bros. Advisors Lp | 10 percent owner | 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014 |
Sean Michael Smith | officer: Principal Accounting Officer | C/O NEOLEUKIN THERAPEUTICS, INC., 188 E. BLAINE STREET, SUITE 450, SEATTLE WA 98102 |
Priti Patel | officer: Chief Medical Officer | C/O NEOLEUKIN THERAPEUTICS, INC., 188 EAST BLAINE STREET, #450, SEATTLE WA 98102 |
Erin Lavelle | director | C/O ALDER BIOPHARMACEUTICALS, INC., 11804 NORTH CREEK PARKWAY SOUTH, BOTHELL WA 98011 |
Donna Cochener | officer: General Counsel, SVP Legal | C/O NEOLEUKIN THERAPEUTICS, INC., 188 EAST BLAINE STREET, SUITE 450, SEATTLE WA 98102 |
Rohan Palekar | director | 201 SPEAR STREET, THIRD FLOOR, SAN FRANCISCO CA 94105 |
Jonathan G Drachman | director, officer: See Remarks | 21823 30TH DRIVE SE, BOTHELL WA 98021 |
Carl Walkey | officer: Senior Vice President | C/O NEOLEUKIN THERAPEUTICS, INC., 360-1616 EASTLAKE AVENUE EAST, SEATTLE WA 98102 |
Robert Ho | officer: Chief Financial Officer | 360-1616 EASTLAKE AVENUE EAST, SEATTLE WA 98102 |
Holly Vance | officer: General Counsel | C/O NEOLEUKIN THERAPEUTICS, INC., 360-1616 EASTLAKE AVENUE E., SEATTLE WA 98102 |
Martin Babler | director | C/O INFINITY PHARMACEUTICALS, INC., 780 MEMORIAL DRIVE, CAMBRIDGE MA 02139 |
Erin M. Lavelle | director | 360-1616 EASTLAKE AVENUE EAST, SEATTLE WA 98102 |
Redmile Group, Llc | 10 percent owner | ONE LETTERMAN DRIVE, BUILDING D, SUITE D3-300, SAN FRANCISCO CA 94129 |
Jeremy Green | 10 percent owner | 45 W. 27TH STREET, FLOOR 11, NEW YORK NY 10001 |
Sarah B. Noonberg | director | 331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080 |
From GuruFocus
By GuruFocusNews GuruFocusNews • 05-09-2022
By GuruFocusNews GuruFocusNews • 05-26-2022
By Value_Insider Value_Insider • 11-14-2022
By Business Wire • 07-25-2023
By GuruFocusNews GuruFocusNews • 06-25-2022
By Marketwired • 07-18-2023
By GuruFocusNews GuruFocusNews • 06-18-2022
By GuruFocusNews GuruFocusNews • 06-15-2022
By PurpleRose PurpleRose • 07-15-2022
By GuruFocusNews GuruFocusNews • 06-08-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.